Method for treating malignant bone tumors

FIELD: medicine.

SUBSTANCE: method involves incubating flasks containing 70-80 ml of blood and 40 ml of preservative agent for 20 min at 37°C together with chemotherapeutical preparations. Next to it, treatment with alternating magnetic field of 50 mTesla units intensity and frequency of 50 Hz is applied at continuous rotation about its axis at 20 rpm speed. 30 mg/m2 of Doxorubicin is added to the first flask contents. 500 mg/m2 of cyclophosphane are added to the second flask and 20 mg/m2 of methotrexate are added to the third flask. Incubation and treatment with alternating magnetic field is started with the first flask at the first and the eighth day. Total chemopreparations quantity is equal to 60-80 mg, cyclophosphan is applied in the amount of 1200-1600 mg, methotrexate - 40 mg.

EFFECT: enhanced effectiveness of treatment.

 

The invention relates to medicine, more specifically to Oncology, and can be used in the complex therapy of patients with tumors in the bone structures.

There is a method of treatment of malignant bone tumors of various histological structures, providing "...surgical treatment as the only method for all malignant bone tumors...". With the exception of osteogenic sarcoma, reticulosarcoma and sarcoma Ewing's sarcoma, which require the combined treatment. The second step is to amputation. ("Oncology", Beiderman, Moscow, "Medicine", 1980).

Suggested by the author of ways of getting rid of the patient from the fire malignant lesions reach the goal. However, carry with them serious injury associated with amputation of limbs during surgical excision of the lesion, which is not always possible to meet due to the location of the tumor (shovel, noplace). Pre - or postoperative chemotherapy, in turn, are not without drawbacks. Both methods have a detrimental effect on the function of tissues and organs, the qualitative composition of the blood, and the time required for normalization of blood counts leading to progression of the malignant process.

There is a method of treatment of patients with sarcomas, developing from the reference tissue, anticancer chemotherapeutic agents when introduced and drugs in a known manner. In the treatment of malignant bone tumors developing from elements of the bone marrow, in the first place are radiation treatments. Special attention is paid to the General effect, as the disease is multiple systemic. After radiotherapy, the author proposes the use of some anticancer drugs. (General Oncology", a guide for physicians, Ed. by Acad. Ipinapakita, Leningrad, Medicine, 1989).

However, these therapeutic effects, as indicated by the author, does not always lead to a positive result. As radiation and chemotherapy bring the deterioration of the General condition of the patient. His weak radiation therapy, the body does not find the strength to resist adverse toxic manifestations of anticancer drugs. All this forces to cease specific antitumor treatment. These complications affect the treatment results.

The aim of the invention is to improve the immediate results of treatment and the possibility of organ-preserving surgical treatment.

This goal is achieved by the fact that patients with malignant bone tumors intravenously administered anticancer medications, United with Autocraft, which from the cubital vein of the patient at the bottles with 40 ml of preservative in each p is izvodyat fence 70-80 ml of blood, incubated at 37°C, then for 10 minutes with continuous rotation around its axis with a speed of 20 revolutions per minute is exposed to an alternating magnetic field induction 50 MT, 50 Hz; in the first vial add doxorubicin 30 mg/m2expose incubation and exposed to an alternating magnetic field, the second 500 mg/m2of cyclophosphamide, incubated, is exposed to an alternating magnetic field, the third - 20 mg/m2methotrexate, incubated, influence of the magnetic field. Introduction mixtures begin with the first bottle. therapeutic effect of the conduct in the first and eighth day of complex therapy. The total number of medications for two of the introduction is: doxorubicin - 60-80 mg of cyclophosphamide - 1200-1600 mg methotrexate - 40 mg

Analysis of the known methods of treatment of malignant bone tumors and developed allows to establish the existence of significant differences and the novelty of the claimed Method of treatment of malignant bone tumors". The novelty of the method lies in the fact that the lesion in the bone structures affect multiple therapeutic factors. The effect of an administered anticancer drugs, incubated with Autocraft patient, after incubation is exposed to an alternating magnetic field with continuous rotation of the vial with Autocraft and chemo is the courthouse square around its own axis. The contents of the vials injected alternately, reinforcing the effect of anticancer drugs.

In open sources of information in Russia, CIS and abroad, a similar method of treatment of malignant bone tumours us could not be found.

The claimed method is industrially applicable. It can be reproduced and repeated many times both in specialized and therapeutic hospitals General medical services.

The method is as follows. After verification of the nature of neoplasms in bony structures of the patient in compliance with the rules of asepsis produce blood from the cubital vein in the amount of 70-80 ml three bottles with 40 ml of preservative in each. Then in the first vial is injected doxorubicin at the rate of 30 mg/m2, and then incubated at 37°C for 20 minutes, exposed to an alternating magnetic field induction 50 MT, 50 Hz for 10 minutes with continuous rotation of the bottle about its axis with a speed of 20 revolutions per minute. After the mixture is injected intravenously. The second vial add cyclophosphamide ratio of 500 mg/m2conduct a similar incubation and exposure to an alternating magnetic field, is re-infused intravenously. In the third vial add methotrexate rate of 20 mg/m2expose incubative the influence of an alternating magnetic field similar modes and injected intravenously. The introduction of anticancer chemotherapy is carried out in the first and eighth days of treatment. A number of medications for two of the introduction is: doxorubicin 60-80 mg of cyclophosphamide - 1200-1600 mg methotrexate - 40 mg. a specific Example can serve as a summary of the history of the disease. Sick o'clock, case history No. 4869, born in 1952, was admitted to the Department of tumours of soft tissue and bone, RNII 5.05.1999, with complaints of swelling of the left shoulder joint, pain, limitation of motion. Objectively admission: in the left shoulder joint tight fixed tumor up to 5 cm in diameter, the skin over the tumor is not changed, the amount of movement in the left shoulder is sharply reduced, there is virtually no sensitivity 4th and 5th fingers of the left hand. Radiographically at entry: determines the area of destruction in the head of the left humerus with the spread of the compact layer. In the cancellous head of the humerus partial areas of calcification. Cytologically No. 9766-67 - dystrophica modified cells chondrosarcoma. Diagnosis at admission: chondrosarcoma of the head of the left humerus T2N0M0phase II, group 2.

11.05.1999, the patient from the cubital vein in three bottles with 40 ml of preservative in each in compliance with the rules of asepsis was taken by 70-80 ml of blood. Then in the first bottle back and doxorubicin 30 mg, then the vial was incubated for 20 minutes at a temperature of 37°With, he was subjected to an alternating magnetic field induction 50 MT, 50 Hz for 10 minutes with continuous rotation of the bottle about its axis with a speed of 20 revolutions per minute. After this mixture was injected intravenously. The second vial was added cyclophosphamide in the amount of 600 mg, produced a similar incubation and exposure to an alternating magnetic field, repusively intravenous drip. The third vial was added 20 mg of methotrexate was subjected to incubation and exposure to an alternating magnetic field similar regimes, introduced intravenously. Introduction the patient underwent fine, nausea and vomiting were missing.

13.05.1999, the General condition of the patient is satisfactory, decreased pain in the left upper extremity. Partially restored sensitivity 4th and 5th fingers of the left hand. Decreased tumor size up to 3 cm in diameter.

19.05.1999, Made repeated administration of chemotherapy drugs in the same doses with the aforementioned method.

20.05.1999 was Done, the x-ray, which stated: partial restoration of normal bone structure, reduced periosteal reaction, a significant decrease in soft tissue component. Objective: education decreased to 2 cm in diameter, decreased tissue swelling was completely restored range of motion in the shoulder joint the sensitivity of the 4th and 5th fingers of the left hand. Decreased pain vanished the need for analgesics.

24.05.1999, Performed organ-sparing surgery - resection of the upper third of the left humerus. Histological type of tumor is well differentiated chondrosarcoma with myxomatosis stroma (HA No. 535203-205). The postoperative period was uneventful. Within two months, fully recovered movement in the elbow and wrist joints. With 9.06.1999, 6.07.1999 course was held remote gamma-therapy in SOD 40 Gr.

23.12.1999, With a regular attendance of the patient is in satisfactory condition.

03.08.2000, the Patient no complaints. Is in satisfactory condition. X-ray and sonography data no relapse. Does the left hand lifting weight 3-5 kg

23.12.2002, the Patient feels quite satisfactorily performs the left hand light housework. Radiographically disease recurrence was not detected.

Technical and economic efficiency "method of treatment of malignant bone tumors is possible:

- to introduce into the body of the patient large doses of anticancer drugs without strengthening their adverse toxic effects;

to avoid disability of the patient in most cases;

- improve the quality of life of patients.

The method of treatment of malignant bone tumors, including the effects of alternating magnetic field and intravenous drip of anticancer chemotherapy, United with Autocraft, characterized in that the vials with 70 to 80 ml of blood and 40 ml of preservative in each together with chemotherapy is subjected during the 20 min incubation at 37°C, then for 10 min, with continuous rotation around its axis with a speed of 20 revolutions per minute vial affected by varying magnetic field induction 50 MT, 50 Hz; in the first vial add doxorubicin 30 mg/m2; in the second 500 mg/m2of cyclophosphamide; in the third vial 20 mg/m2methotrexate; incubation, the influence of an alternating magnetic field is carried out, starting with the first bottle, the first and eighth days of treatment, the total number of chemotherapy drugs is 60-80 mg of cyclophosphamide 1200-1600 mg, methotrexate 40 mg



 

Same patents:

FIELD: medical engineering.

SUBSTANCE: device has alternating low frequency electromagnetic field generator manufactured as at least three adjacent coaxially mounted electromagnetic systems, each having five autonomous cores having excitation windings having independent electric power supply sources allowing independent on/off switching, varying phases and current intensity supplied to each of them. The cores embrace working volume with radiating end faces.

EFFECT: selective functional activity treatment of tissue structure cells in injury zone with alternating low frequency magnetic field; reduced risk of negative action upon neighboring healthy organs and tissues.

4 dwg

FIELD: medicine.

SUBSTANCE: method involves applying combined trans-spinal micro-polarization and pulsed stimulation. The trans-spinal micro-polarization is carried out using constant current of 100-300 mcA by applying skin electrodes of 20-35 cm large area. The trans-spinal micro-polarization is carried out during 30-40 min. Anode is placed lateral with respect to spinal process of the seventh vertebra C7 and cathode is placed contralaterally with respect to the anode in lumbosacral zone at the level of spinal processes of L5-S1. Magnetic pulsed stimulation is carried out with short pulses having two in every emitted package. Magnetic induction amplitude of the first pulse is equal to 1400 mTesla units and of the second one is less by 55%. The pulses are sent along the right and left side of the vertebral column in turn giving 3-4 packages per each spine segment. Stimulation is started beginning from cervical segment. The total treatment course is 6-7 procedures long with pauses being not longer than 2 days.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying alternating sinusoid magnetic field in cyclically alternating frequency mode of 100:10 Hz with magnetic field intensity of 35 mTesla units and pulsing-to-action duration proportion of 3:1 and treatment duration of 15-20 min. Alternating magnetic field is applied concurrently with drug electrophoresis of 5% magnesium sulfate for 15-20 min. The total treatment course is 7-8 daily procedures long.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves applying running pulsating magnetic field to lumbar sympathetic nodes projection region and local magnetic vibroacoustic treatment to paravertebral cervical vertebral column segment zones. Running pulsating magnetic field of amplitude value of magnetic field intensity equal to 20±3 mTesla units on working surface of inductors, pulse duration equal to 1.5±2.5 ms and pulse succession frequency equal to 6 Hz, is used. Magnetic vibroacoustic treatment is applied with amplitude value of magnetic field intensity equal to 30±9 mTesla units and sound pressure intensity on working surface of vibroacoustic emitter equal to 2.2±0.9 Pa in bandwidth of 0.02 to 20 kHz.

EFFECT: accelerated treatment course; stimulated stress-limiting systems.

FIELD: medicine, physiotherapy.

SUBSTANCE: one should apply "Relict-05" gel onto painful articular surfaces at the quantity of 1-3 ml, perform magnetophoresis followed by cross-sectional induction at constant mode, 15 mTl, frequency 50 Hz, 10 procedures. It is necessary to conduct 1-2 courses at interval up to 2 wk. The method restores circulation in cartilaginous, subchondral and synovial tissues.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves applying group halo therapy to 5-7 years old children during 15-20 min, to more than 7 years old children during 25-30 min daily in a 10-15 procedures long course and 8-10 procedures long daily magnetotherapy course. Magnetotherapy is administered after every 5-6 halo therapy procedures. The treatment is carried out with low frequency alternating magnetic field applied to submandibular region with magnetic field intensity being equal to 6-9 mTesla units during 5-7 min to the right and left side. Total treatment time is equal to 10-14 min.

EFFECT: enhanced effectiveness of treatment; activated local humopral and cellular mucous membrane protection factors.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves administering 10 treatment sessions comprising sequential introduction of medicaments selected from groups like coagulants, disaggregants, corticosteroids and antioxidants, treating an eye with pulsating magnetic field of 10-12 mTesla units large intensity, frequency of 50 Hz applied for 10 min and retinal laser coagulation treatment with diode laser having wavelength of 810 nm. The medicaments are administered into retrobulbar space twice a day with 30 min long interval. The medicaments are introduced into the retrobulbar space via catheter implanted in advance.

EFFECT: enhanced effectiveness of treatment; high medicament concentration in pathological focus; stimulated medicament action; eliminated edemas.

2 cl

FIELD: medicine.

SUBSTANCE: method involves applying synchronous treatment with magnetic field intensity of 1.2-2 Tesla units in epileptic activity focus projection and with magnetic vortex field intensity of 0.2 Tesla units which effective frequencies are determined from invoked potential drop showing electric activity of brain and from epi-symptoms drop on electroencephalogram before and after applying transcranial magnetic stimulation. The treatment is applied daily for 15-30 min. The total treatment course is 10-20 sessions long.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves applying thermomagnetic self-excitation inductance treatment of 1.2-2 Tesla units in subcortical nuclei projection with effective frequencies detected from increased amplitude of somatosensory and motor invoked potential and dophamine level growth in blood or liquor, reduced basic rhythm disorganization on electroencephalogram before and after applying thermomagnetic self-excitation inductance treatment. Synchronized median nerve electrostimulation with rectangular pulses is concurrently carried out with current intensity equal to 12-18 A and pulse duration of 0.1-0.l3 ms in trains of 3-5 s duration and 6-10 s long pauses with pulse succession frequency equal to 50 Hz daily during 15-30 min. The total treatment course is 10-20 days long.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves applying low frequency magnetic field of 25-30 mTesla units intensity to front region using magnetic amplipulse galvanotherapy apparatus during 8-10 min. The total treatment course is 10-12 daily procedures long.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine, gynecology, pharmacy.

SUBSTANCE: invention proposes using pimafucin (natamycin) as agent for treatment of bacterial vaginitis. Method for treatment of bacterial vaginitis involves intravaginal administration of pimafucin as 2% cream, 2 times per a day in morning and evening for 7-10 days and for first 3 days pimafucin-containing vaginal suppository in the dose 100 mg is administrated additionally in evening after administration of cream into vagina. Invention provides high effectiveness of treatment and clinical-etiological recovery in 92.3% of cases being without prescription of medicinal preparations. Method has no contraindications and can be used in all period of pregnancy and without adverse effects.

EFFECT: improved treatment method, enhanced effectiveness of agent and treatment.

2 cl, 1 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating locally metastasing forms of bladder's cancer at T2b-4N0-1M0 stages. It deals with performing chemotherapy due to fractional introduction of total therapeutic dosage of cytostatic preparation into pubic bone - adriamycin at a single dosage being not more than 30 mg every other day per one course up to total dosage of 70 mg/m2. After each injection one should introduce per 2 ml 2%-lidocaine solution through the same needle. For patients with contra-indications for systemic chemotherapy total adriamycin dosage should be decreased twice to be distributed for three injections. The method increases adriamycin concentration in tumor at optimal way and mode of its injection by providing decreased number of toxic complications, in patients above 75 or with severe accompanied pathology, among them.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: organic chemistry, veterinary science.

SUBSTANCE: invention relates to a method for control over exto- and endoparasites taken among group including acariform mites, parasitoformous mites and nematodes parasitizing in animals, productive cattle and domestic animals. Method involves applying veterinary preparation comprising 1-[4-chloro-3-(3-chloro-5-trifluoromethyl-2-pyridyloxy)phenyl]-3-(2,6-difluoro)urea and compound of the formula (i):

wherein R1 means one of radicals:

or ; R2 means -CH(CH3)-CH3, -CH(CH3)-C2H5, -C(CH3)=CH-CH(CH3)2 or cyclohexyl; R3 means hydrogen atom or hydroxy-group if a bond between atoms 22 and 23 represents a double bond, or it means hydrogen atom or group =N-O-CH3 if an ordinary bond presents between atoms 22 and 23; R4 means HO-, and the preparation can be in free form or in physiologically acceptable form. Invention provides preparing preparations with good tolerance and rapid effect and persistence with respect to different helminth-associated diseases, parasitiformous and acariformous mites being without adverse effect on normal behavior of animals.

EFFECT: valuable properties of compounds.

7 cl, 3 tbl, 8 ex

FIELD: organic chemistry, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to new compounds - pluraflavines of the formula (I): wherein R1 represents sugar group of the formula: ; R2 represents -COOH or -CH2-O-(R7)m wherein R7 represents sugar group of the formula: ; R3 is taken among the groups: and , and to all its stereochemical forms and mixtures of indicated forms in any ratio, and to their physiologically acceptable salts; R5 means hydrogen atom; R4 and R6 represent in common group -X2 with a double bond wherein X2 means oxygen atom (O); R8 and R10 represent in common group -X2 with a double bond wherein X2 means oxygen atom (O), and m = n = 1, and to all its stereochemical forms and mixtures of indicated forms in any ratio and to its physiologically acceptable salts. Invention relates to a method for preparing these compounds from culture of microorganism actinomycetes HAG 003959, DSM 12931 by fermentation, to the strain Actinomycetales HAG 003959, DSM 12931 used for preparing compounds of the formula (I) and to pharmaceutical composition inhibiting transcriptase activity and eliciting cytotoxic effect based on above said compounds. Compounds of the formula (I) are used as medicinal agents, for example, as antitumor agents.

EFFECT: improved method for preparing, valuable medicinal properties of compounds and composition.

19 cl, 3 tbl, 12 ex

FIELD: medicine, pharmacy, pharmaceutical technology.

SUBSTANCE: invention relates to an antibacterial preparation azithromycin. The stable pharmaceutical suspension of azithromycin comprises the therapeutically effective dose of azithromycin and special additives - sorbitol, sodium benzoate, aromatic principles, glycerol, glutamic acid, methylcellulose, polyvinylpyrrolidone and propylene glycol. Also, invention proposes a method for preparing the stable suspension of azithromycin that involves addition of mixture of azithromycin with glutamic acid as solution in glycerol or as dry form to an aqueous solution of methylcellulose containing propylene glycol and glycerol or propylene glycol and successively dissolved sodium benzoate, polyvinylpyrolidone and sorbitol followed by dilution with water up to the azithromycin concentration that is necessary for using. Invention provides creature of new stable suspension that is resistant for 1 year, not less, and useful for treatment of children being among them suffering with diabetes mellitus.

EFFECT: improved method for preparing, valuable medicinal properties of suspension.

4 cl, 4 tbl, 1 dwg, 4 ex

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to study for effect of niglisine representing a derivative of glycyrrhizic acid. Invention proposes an agent for induction of gamma-interferon under conditions in vitro and in vivo. Invention proposes glycyrrhizic acid penta-O-nicotinate as such agent that is known early as an anti-inflammatory agent and inhibitor of HIV reproduction. Niglisine in the range of concentrations 0.167-6 mcg/ml enhances significantly the secretion of gamma-interferon by blood mononuclear cells that will allow its using for non-specific protection of body.

EFFECT: valuable properties of gamma-interferon inductor.

1 tbl, 3 dwg

FIELD: pharmaceutical industry.

SUBSTANCE: new urogenital drug contains 50-250 g antibacterially efficient antibiotic erythromycin, 50-250 g antifungally efficient antibiotic nistatin, antiprotozoal preparation metronidazole, and 1.5-3.5 g (to complete weight of suppository) A type solid fat as filler. Drug can be used to treat mixed urogenital infections.

EFFECT: reduced treatment time, lowered recurrence of diseases, lack of adverse effects, and lowered cost.

FIELD: medicine.

SUBSTANCE: the present innovation includes polychemotherapy and radiation therapy. Moreover, polychemotherapy should be carried out by the following scheme: on the 1st and the 8th d of the first and the third courses it is necessary to introduce doxorubicin, cyclophosphan, vincristine, and since the 1st to the 14th d - procarbazine and prednisolone; moreover, on the 1st and the 8th d of the second and the fourth courses one should introduce doxorubicin, bleomycin, vinblastine, dacarbazine. The method enables to decrease the quantity of late therapeutic complications, improves the results of relapse-free, total tumor-specific survival rate and decreases the number of polychemotherapeutic cycles.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating oncological diseases. It is suggested to apply bisdioxopiperazine (previously known as cardioprotector) to either treat or prevent tissue lesions caused due to sporadic transudation of cytotoxic poison for topoisomerase II (represented by anthracyclines, etoposide, teniposide, mitoxantrone daunorubicin, doxorubicin, etc.), medicinal remedies and pharmaceutical set of the same indication. It is, also, suggested to apply the method to treat or prevent tissue lesions caused by sporadic transudation of topoisomerase II poison. BisdioxopiperazineICRF-187 has impact due to catalytic inhibiting topo II. Signs for possible transudation of topoisomerase II poison (of local toxicity) usually include the availability of acute pain, erythema, development of ulcerations in area of transudation; due to the action of ICRF-187 the quantity of wounds is reduced, or the development of side effects is not observed.

EFFECT: higher efficiency of therapy.

59 cl, 12 dwg, 13 ex, 10 tbl

FIELD: chemical engineering; pharmaceutical engineering.

SUBSTANCE: method involves applying substances of macrolide group showing high inhibition degree with respect to protein of tyrosine kinase.

EFFECT: enhanced effectiveness in suppressing infection and proliferation of human immune deficiency virus in macrophages.

4 cl, 25 dwg

FIELD: medicine, oncology, gynecology.

SUBSTANCE: method involves external irradiation and using chemopreparations combined with autoplasma. External irradiation in the dose 2 Gr is carried out from 1 to 4 day of treatment followed by intravenous administration of cisplatin on 5 day in the dose 10 mg with 250 ml of physiological solution. On the following day 10 ml of autoplasma incubated with 10 mg of cisplatin is administrated by paratumoral route by right and left of tumor into paravaginal cellular tissue and by intratumoral route into projection of cervical channel. Blood cellular elements are incubated with 600 mg of cyclophosphane and reinfused by intravenous drop route. Effects are repeated in indicated sequence once per a week, 4 times per treatment course. Method provides increasing percent of tumor regression due to the complex effect on tumor, enhancing the topical concentration of cytostatic drug and prolongation of its contact in malignant growth zone, and providing radiosensibilizing effect in diminishing the general toxic effect of therapy. Invention can be used in treatment of patients with topically disseminated forms of uterus cervix cancer at the stage T3NxM0.

EFFECT: improved and enhanced treatment method.

1 ex

Up!